CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 149 enrolled
Drug / intervention
Duloxetine Hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03315793
NCT03315793Phase 3Completed
CompareCT.gov

A Double-blind, Efficacy and Safety Study of Duloxetine Hydrochloride Versus Placebo in the Treatment of Japanese Children and Adolescents With Depressive Disorder

Shionogi·interventional·Posted Oct 20, 2017·Updated Jan 5, 2021

In Brief

A Phase 3 clinical trial evaluating Duloxetine Hydrochloride and Placebo for Depressive Disorder. Completed, enrolled 149 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus placebo in the treatment of Japanese children and adolescents with depressive disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder
CountriesJapan
CollaboratorsEli Lilly and Company

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedOct 20, 2017
Enrollment StartDec 4, 2017
Primary CompletionNov 8, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.7 years ago

Interventions

Duloxetine Hydrochloridedrug

Administered orally

Placebodrug

Administered orally